Cara Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) announced participation by CEO Christopher Posner in two investor conferences this November. The Stifel 2021 Virtual Healthcare Conference will host a fireside chat on November 15 at 1:20 p.m. ET, and the Jefferies London Healthcare Conference will feature a chat on November 18 at 3:00 a.m. ET. Webcasts will be accessible via the company's website and archived for 30 days. Cara Therapeutics focuses on developing treatments to alleviate pruritus through its innovative drug, KORSUVA, which recently received FDA approval for treating CKD-aP.

STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Christopher Posner, President and Chief Executive Officer, will participate in the following upcoming investor conferences in November:

Stifel 2021 Virtual Healthcare Conference, November 15, 2021 – November 17, 2021
Fireside Chat on Monday, November 15, 2021 at 1:20 p.m. ET

Jefferies London Healthcare Conference, November 16, 2021 – November 19, 2021
Fireside Chat on Thursday, November 18, 2021 at 3:00 a.m. ET

Webcasts of the fireside chats can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. KORSUVA injection was approved by the FDA for the treatment of moderate-to-severe CKD-aP in adults undergoing hemodialysis on August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in PBC and NP patients with moderate-to-severe pruritus.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com

FAQ

What is Cara Therapeutics participating in November 2021?

Cara Therapeutics will participate in the Stifel 2021 Virtual Healthcare Conference and the Jefferies London Healthcare Conference.

When is the Stifel 2021 Virtual Healthcare Conference?

The Stifel 2021 Virtual Healthcare Conference is from November 15 to November 17, 2021.

What time is Cara Therapeutics' fireside chat at the Stifel conference?

The fireside chat at the Stifel conference is scheduled for November 15, 2021, at 1:20 p.m. ET.

When is the Jefferies London Healthcare Conference?

The Jefferies London Healthcare Conference takes place from November 16 to November 19, 2021.

What time is Cara Therapeutics' fireside chat at the Jefferies conference?

The fireside chat at the Jefferies London Healthcare Conference is set for November 18, 2021, at 3:00 a.m. ET.

Where can I watch the webcasts of Cara Therapeutics' fireside chats?

The webcasts can be accessed on Cara Therapeutics' website under 'Events & Presentations,' and will be archived for 30 days.

What is KORSUVA and its significance?

KORSUVA is a first-in-class KOR agonist developed by Cara Therapeutics, recently approved by the FDA for treating moderate-to-severe CKD-aP.